Muhimbili University of Health And Allied Sciences
Dar es Salaam, PO BOX 65001, Tanzania
NCT Number: NCT01115478
The purpose of this study is to determine the efficacy of zinc and/or vitamin A supplementation in reducing the risk of placental malaria and its associated adverse pregnancy outcomes.
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Not applicable
Dar es Salaam, PO BOX 65001, Tanzania
Malaria accounts for a major proportion of the disease burden in Tanzania with 14 to 18 million new malaria cases being reported each year resulting in 100,000-125,000 deaths. Malaria results in impaired productivity for those between 15-55 years and lost learning opportunities in the 5-25 year age group. Dar es Salaam is characterized as an area with endemic and perennial malaria, with transmission occurring during the entire year. P. falciparum accounts for more than 95% of malaria infections. A number of interventions have contributed to reducing the burden of the disease in some settings in Tanzania and beyond, including vector control measures, bed nets, and prophylaxis and treatment of malaria. However, malaria remains a serious problem among pregnant women and children. We will examine the efficacy of micronutrient supplements as a means of enhancing immune response to malaria in pregnancy and reducing the risks of associated adverse clinical outcomes. If successful, such a low-cost intervention would be added to the armamentarium against this disease.
NOTE: The time frames listed for the maternal malaria and hemoglobin outcomes were updated on 4/22/15. This record initially indicated that maternal malaria anemia and hemoglobin would be measured at several specific time points throughout the study. Instead, maternal malaria was measured throughout pregnancy and hemoglobin was measured only at delivery. Due to an oversight, we did not update this record when this protocol change took effect at the start of the study.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Daily oral dose of 2500 IU from enrollment until delivery
Daily oral dose of 25 mg from enrollment until delivery
Daily oral dose from enrollment until delivery
Time frame: Delivery
Placental infection status will be categorized as infected if there are asexual parasites in the placenta blood; not infected if the placental blood smear is negative; or status unknown if no placental smear is available.
Time frame: Delivery
Low birth weight will be defined as birth weight less than 2500 grams.
Time frame: Delivery
Anemia is defined as hemoglobin less than 11 g/dl. Severe anemia is less than 8.5 g/dl.
Time frame: at or after 28 weeks of gestation and in the first 7 days of life
Time frame: During pregnancy
Maternal malaria will be defined as fever within the last 72 hours with any parasitemia on a peripheral blood smear.
Harvard School of Public Health (HSPH)
Other
Acronym: MAL2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03897673
Anemia, Anemia in Children
Kampala, Uganda
View Trial DetailsNCT03931473
Anemia, Hematologic Diseases
Cové, Benin
View Trial DetailsNCT04858087
Anemia, Hematologic Diseases
View Trial DetailsNCT00367380
Anemia, Body Temperature Changes
Cali, Valle del Cauca Department, Colombia
View Trial Details